[A21-08] Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2021
Project no.:
A21-08
Commission:
Commission awarded on 15.01.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with multiple myeloma who have received at least one prior therapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
| Project no. | Title | Status |
|---|---|---|
| A17-38 | Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-11 | Carfilzomib (multiple myeloma; combination with dexamethasone alone) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| G15-16 | Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
| A21-70 | Carfilzomib (multiple myeloma) - Addendum to Commission A21-08 | Commission completed |
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.